Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. Feb. 6, 2019. Tom Buckland.

Executive Summary

Scottish device firm Sirakoss has received European clearance for its Osteo3 synthetic bone graft substitute. Tom Buckland, director of Sirakoss, says the company's primary focus is to continue clinical studies to improve surgeon experience with Osteo and prepare for entry into a highly populated space. Read his comments here.

"If commercial opportunities arise as part of these clinical activities, we will evaluate them on a case-by-case basis. Synthetic bone grafting is a crowded field, with many options for surgeons available and many unsubstantiated performance claims being made on the basis of minor technical differences between products. Based on what we believe are significant technical advantages and robust performance data obtained to date, Sirakoss considers that the most effective way to differentiate Osteo3is on the basis of clinical outcome data. We will now run additional clinical studies to validate our development and strategy." –Tom Buckland, director, Sirakoss

Click here for a free trial of Medtech Insight



Related Content

Scotland's Sirakoss Scores CE Mark For New Bone Graft Technology





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts